Volume 2, Issue 9, Page 1 (September 2006)
1 of 32
PREVIEW
FULL TEXT
FULL-TEXT PDF (201 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
Investigational drugs that decrease the body's load of both soluble and fibrillar amyloid β (Aβ) could change a diagnosis of Alzheimer's disease from a death sentence to that of a chronic but manageable illness.
PII: S1553-3212(06)71631-4
doi:10.1016/S1553-3212(06)71631-4
© 2006 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
PREVIEW